In Q1 2023, Deep Track Capital held 38 positions worth $1.8B. They initiated 38 new positions. Their largest holding was JAZZ ($175.6M).
Frequently asked questions
What stocks did Deep Track Capital own in Q1 2023?
Deep Track Capital held 38 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include JAZZ, TVTX, IMVT, INSM, IONS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q1 2023?
Deep Track Capital's tracked biotech portfolio was worth $1.8B across 38 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q1 2023?
Deep Track Capital initiated 38 new positions in Q1 2023, including JAZZ, TVTX, IMVT, INSM, IONS and 33 more. They also increased 0 existing positions.
What did Deep Track Capital sell in Q1 2023?
Deep Track Capital did not fully exit any positions in Q1 2023.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capital portfolio →